Celltrion Offers Real-World Data On Rituximab

Presents New Data On Truxima Biosimilar In Diffuse Large B-cell Lymphoma Patients

24 Jun 2021

• By Akriti Seth

South Korea’s Celltrion has announced positive results from its recent study on the real-world clinical effectiveness and safety of its Truxima (rituximab) or CT-P10 biosimilar in patients with diffuse large B-cell lymphoma. The company presented its findings at the recently held European Hematology Association 2021 virtual congress.

clinical trials — Celltrion’s rituximab is found to be safe for patients with diffuse large B-cell lymphoma • Source: Alamy

Celltrion has presented new data from its multi-country retrospective post-approval study evaluating the real-world clinical effectiveness and safety of its Truxima (rituximab) or CT-P10 biosimilar in patients with diffuse large B-cell lymphoma at the European Hematology Association 2021 virtual congress.

Commenting on the results of the study, HoUng Kim, head of the medical and marketing division at Celltrion Healthcare, said...